Financial press releases
Patent registered in Eurasia to protect the Cesium decorporation drug candidate – Dec. 12, 2022
Medesis Pharma presents a scientific poster at the clinical trials on alzheimer’s disease conference in San Francisco – Nov. 28, 2022
Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases – Nov. 21, 2022
Medesis Pharma further strengthens its governance – Oct. 4, 2022
Medesis receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD RNA interference therapy for Huntington’s disease – July 20, 2022
Treatment of Alzheimer’s disease with Nanolithium first inclusion of patients in the phase II clinical study – June 13, 2022
Development of NanoManganese for the optimization of radiotherapy in cancer treatment – April 20, 2022
2021 full-year business and earnings – April 13, 2022
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy – April 5, 2022
U.S. patent protection registration of the future drug allowing the decorporation of cesium – March 24, 2022